Tag: HY-091
AFT Pharmaceuticals spearheads progress in women’s health with Hyloris partnership
AFT Pharmaceuticals announced its partnership with Hyloris Pharmaceuticals, based in Belgium, to develop a novel treatment, HY-091, for Vulvar Lichen Sclerosus (VLS), addressing the critical need for effective solutions in an area where approved treatments are limited.
Featured Article
Australian manufacturing in 2025: Challenges and pathways to progress
The Australian manufacturing sector, long considered the backbone of the nation’s economy, is standing at a crossroads in 2025.
